Literature DB >> 20016471

Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease.

Daniela V Barreto1, Fellype C Barreto, Sophie Liabeuf, Mohammed Temmar, Horst-Dieter Lemke, Christophe Tribouilloy, Gabriel Choukroun, Raymond Vanholder, Ziad A Massy.   

Abstract

Chronic inflammation associated with chronic kidney disease predicts all-cause and cardiovascular mortality in hemodialysis patients. Here we sought to evaluate the association between plasma levels of the inflammatory mediator interleukin-6 (IL-6) and mortality and aortic calcification/stiffness in 125 patients at different stages (2-5D) of chronic kidney disease. Using multivariate linear regression, we found that plasma IL-6 was independently associated with C-reactive protein, albumin and the stage of chronic kidney disease, but not the aortic calcification score or pulse wave velocity. During follow-up studies (median of 829 days), 38 patients died, 22 from cardiovascular events. Plasma IL-6 significantly predicted overall and cardiovascular mortality; this association persisted after multiple adjustments or restricting the analysis to pre-dialysis patients. Moreover, IL-6 was a significantly better predictor of mortality than C-reactive protein, albumin or tumor necrosis factor-alpha. Hence, plasma IL-6 independently predicted overall and cardiovascular mortality in patients at different stages of chronic kidney disease; however, whether lowering plasma IL-6 will affect the outcome of chronic kidney disease will require more direct evaluation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20016471     DOI: 10.1038/ki.2009.503

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  103 in total

Review 1.  The bone-vascular axis in chronic kidney disease.

Authors:  Linda Demer; Yin Tintut
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-07       Impact factor: 2.894

2.  Mild renal dysfunction and long-term adverse outcomes in women with chest pain: results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE).

Authors:  Rajesh Mohandas; Mark Segal; Titte R Srinivas; B Delia Johnson; Xuerong Wen; Eileen M Handberg; John W Petersen; George Sopko; C Noel Bairey Merz; Carl J Pepine
Journal:  Am Heart J       Date:  2015-01-06       Impact factor: 4.749

3.  Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.

Authors:  Eva Schepers; Daniela V Barreto; Sophie Liabeuf; Griet Glorieux; Sunny Eloot; Fellype C Barreto; Ziad Massy; Raymond Vanholder
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-04       Impact factor: 8.237

Review 4.  Statins, inflammation and kidney disease.

Authors:  Vera Krane; Christoph Wanner
Journal:  Nat Rev Nephrol       Date:  2011-05-31       Impact factor: 28.314

Review 5.  Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis

Authors:  Paul M Ridker
Journal:  Circ Res       Date:  2019-02       Impact factor: 17.367

6.  Accumulation of retained nonfunctional arteriovenous grafts correlates with severity of inflammation in asymptomatic ESRD patients.

Authors:  Haimanot Wasse; Francesca Cardarelli; Christine De Staercke; W Craig Hooper; Qi Long
Journal:  Nephrol Dial Transplant       Date:  2012-10-22       Impact factor: 5.992

7.  Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD.

Authors:  Belinda Spoto; Francesco Mattace-Raso; Eric Sijbrands; Daniela Leonardis; Alessandra Testa; Anna Pisano; Patrizia Pizzini; Sebastiano Cutrupi; Rosa M Parlongo; Graziella D'Arrigo; Giovanni Tripepi; Francesca Mallamaci; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-09       Impact factor: 8.237

Review 8.  Heart failure and kidney dysfunction: epidemiology, mechanisms and management.

Authors:  Joerg C Schefold; Gerasimos Filippatos; Gerd Hasenfuss; Stefan D Anker; Stephan von Haehling
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

9.  Growth arrest-specific gene 6 (Gas6) levels are elevated in patients with chronic renal failure.

Authors:  Iris J Lee; Brendan Hilliard; Abhishek Swami; John C Madara; Swati Rao; Tapan Patel; John P Gaughan; Jean Lee; Crystal A Gadegbeku; Eric T Choi; Philip L Cohen
Journal:  Nephrol Dial Transplant       Date:  2012-08-20       Impact factor: 5.992

10.  Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease.

Authors:  Saurav Singh; Alexander Grabner; Christopher Yanucil; Karla Schramm; Brian Czaya; Stefanie Krick; Mark J Czaja; Rene Bartz; Reimar Abraham; Giovana S Di Marco; Marcus Brand; Myles Wolf; Christian Faul
Journal:  Kidney Int       Date:  2016-07-22       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.